Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 53

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 53
---
 contractual restrictions that could harm our business relationships, financial condition, results of operations, and business, including:

| • |     | difficulties maintaining existing and/or establishing business relationships, including business relationships 
 with significant partners;                                                                                     |

| • |     | the possibility of disruption to our business and operations resulting from the announcement and pendency of the 
 Divestiture, including diversion of management attention and resources;                                          |

| • |     | the inability to attract and retain key personnel and recruit prospective employees, and the possibility that our                
 current employees could be distracted, and their productivity decline as a result, due to uncertainty regarding the Divestiture; |

| • |     | the inability to pursue alternative business opportunities or make changes to our business pending the completion 
 of the Divestiture, and other restrictions on our ability to conduct our business;                                |

| • |     | our inability to freely issue securities, incur certain indebtedness, declare or authorize any dividend or 
 distribution, or make certain material capital expenditures without Kaken’s approval;                      |

| • |     | our inability to solicit other acquisition proposals during the pendency of the Divestiture under the terms of 
 the Divestiture Agreement;                                                                                     |

| • |     | the amount of the costs, fees, expenses, and charges related to the Divestiture Agreement and the Divestiture,                                                                                                
 including but not limited to the cost of professional services, insurance, and any legal proceeding that may be instituted against us, which may materially and adversely affect our financial condition; and |

- 36 -

| • |     | other developments beyond our control, including, but not limited to, changes in domestic or global economic 
 conditions that may affect the timing or success of the Divestiture.                                         |

If any of these effects were to occur, it could adversely impact our business, cash flow, results of operations or financial condition, as well as the market price of our common stock and our perceived value, regardless of whether the Divestiture is completed. The announcement and pendency of the Divestiture, whether or not completed, may adversely affect our business and operations. The announcement and pendency of the Divestiture, whether or not completed, may adversely affect the trading price of our common stock as well as our relationships with existing or potential suppliers, customers, vendors, distributors, licensors, licensees, collaboration partners and other business partners, and may have an adverse effect on the business, financial condition and results of operations of Aadi. The